www.fgks.org   »   [go: up one dir, main page]
This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!
Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Synthesis and biological activities of a pH-dependently activated water-soluble prodrug of a novel hexacyclic camptothecin analog.
Ohwada J, Ozawa S, Kohchi M, Fukuda H, Murasaki C, Suda H, Murata T, Niizuma S, Tsukazaki M, Ori K, Yoshinari K, Itezono Y, Endo M, Ura M, Tanimura H, Miyazaki Y, Kawashima A, Nagao S, Namba E, Ogawa K, Kobayashi K, Okabe H, Umeda I, Shimma N. Ohwada J, et al. Bioorg Med Chem Lett. 2009 May 15;19(10):2772-6. doi: 10.1016/j.bmcl.2009.03.123. Epub 2009 Mar 28. Bioorg Med Chem Lett. 2009. PMID: 19362835
Synthesis of new camptothecin analogs with improved antitumor activities.
Niizuma S, Tsukazaki M, Suda H, Murata T, Ohwada J, Ozawa S, Fukuda H, Murasaki C, Kohchi M, Morikami K, Yoshinari K, Endo M, Ura M, Tanimura H, Miyazaki Y, Takasuka T, Kawashima A, Nanba E, Nakano K, Ogawa K, Kobayashi K, Okabe H, Umeda I, Shimma N. Niizuma S, et al. Among authors: ohwada j. Bioorg Med Chem Lett. 2009 Apr 1;19(7):2018-21. doi: 10.1016/j.bmcl.2009.02.031. Epub 2009 Feb 12. Bioorg Med Chem Lett. 2009. PMID: 19254843
A water soluble prodrug of a novel camptothecin analog is efficacious against breast cancer resistance protein-expressing tumor xenografts.
Endo M, Miwa M, Ura M, Tanimura H, Taniguchi K, Miyazaki Y, Ohwada J, Tsukazaki M, Niizuma S, Murata T, Ozawa S, Suda H, Ogawa K, Nanba E, Nagao S, Shimma N, Yamada-Okabe H. Endo M, et al. Among authors: ohwada j. Cancer Chemother Pharmacol. 2010 Jan;65(2):363-71. doi: 10.1007/s00280-009-1042-5. Cancer Chemother Pharmacol. 2010. PMID: 19495753
Discovery and biological activity of a novel class I PI3K inhibitor, CH5132799.
Ohwada J, Ebiike H, Kawada H, Tsukazaki M, Nakamura M, Miyazaki T, Morikami K, Yoshinari K, Yoshida M, Kondoh O, Kuramoto S, Ogawa K, Aoki Y, Shimma N. Ohwada J, et al. Bioorg Med Chem Lett. 2011 Mar 15;21(6):1767-72. doi: 10.1016/j.bmcl.2011.01.065. Epub 2011 Jan 22. Bioorg Med Chem Lett. 2011. PMID: 21316229
Optimization of the phenylurea moiety in a phosphoinositide 3-kinase (PI3K) inhibitor to improve water solubility and the PK profile by introducing a solubilizing group and ortho substituents.
Kawada H, Ebiike H, Tsukazaki M, Yamamoto S, Koyama K, Nakamura M, Morikami K, Yoshinari K, Yoshida M, Ogawa K, Shimma N, Tsukuda T, Ohwada J. Kawada H, et al. Among authors: ohwada j. Bioorg Med Chem. 2016 Jul 1;24(13):2897-2906. doi: 10.1016/j.bmc.2016.04.060. Epub 2016 Apr 28. Bioorg Med Chem. 2016. PMID: 27189888
21 results